Potential role of TRAIL in the management of autoimmune diabetes mellitus

Current Pharmaceutical Design

Volumn 18, Issue 35, 2012, Pages 5759-5765

  Bernardi, Stella ^a   Norcio, Alessia ^b   Toffoli, Barbara ^c   Zauli, Giorgio ^b   Secchiero, Paola ^d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Apoptosis; Autoimmune diabetes mellitus; Signal transduction; TRAIL

Indexed keywords

ANTIDIABETIC AGENT; GAD 65; INSULIN; PROTECTIVE AGENT; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; DIABETIC RETINOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84870180766     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803530925     Document Type: Review

References (75)

1. Myers M, Zimmet P. Halting the accelerating epidemic of type 1 diabetes. Lancet 2008; 371: 1730-1.
2. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008; 371: 1777-82.
3. Van Belle TL, Coppieters KT, and Von Herrath MG. Type 1 diabetes: etiology, immunology and therapeutic strategies. Physiol Rev 2011; 91: 79-118.
4. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet 1986; 2: 119-24.
5. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37: 1574-1582.
6. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomized, double- blind, phase II trial. Lancet 2001; 358: 1749-1753.
7. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763-1769.
8. Lugdvigsson J, Faresjo M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:1909-20.
9. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366:433-42.
10. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117: 3857-67.
11. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331-40.
12. Secchiero P, Zauli G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol 2008; 15: 42-8.
13. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14: 619-33.
14. Nerup J, Andersen OO, Bendixen G, et al. Cell-mediated autoimmunity in diabetes mellitus. Proc R Soc Med 1974; 67: 506-10.
15. Buschard K, Madsbad S, and Rygaard J. Depressed suppressor cell activity in patients with newly diagnosed insulin-dependent diabetes mellitus. Clin Exp Immunol 1980; 41: 25-32.
16. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7: 585-98.
17. Sakaguchi S, Powrie F, and Ransohoff RM. Re-establishing immunological self-tolerance in autoimmune disease. Nat Med 2012; 18: 54-8.
18. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-cell deficiency. N Engl J Med 2001; 345: 1036-9.
19. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117: 3857-67.
20. Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B- lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-52.
21. Roep, BO. The role of T-cells in the pathogenesis of Type 1 diabe- tes: from cause to cure. Diabetologia 2003; 46: 305-321.
22. Eisenbarth GS. Type 1 diabetes mellitus. N Engl J Med 1986; 314: 1360-8.
23. Bottazzo GF, Mann JI, Thorogood M, Baum JD, Doniach D. Auto- immunity in juvenile diabetics and their families. Br Med J 1978; 2: 165-168.
24. Koczwara K, Bonifacio E, and Ziegler AG. Transmission of mater- nal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. Diabetes 2004; 53:1-4.
25. Di Lorenzo TP, Peakman M, and Roep BO. Translational mini- review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148:1-16.
26. Hamilton-Williams EE, Palmer SE, Charlton B, Slattery RM. Beta cell MHC class I is a late requirement for diabetes. Proc Natl Acad Sci USA 2003; 100: 6688-93.
27. Mandrup-Poulsen T. -cell apoptosis. Diabetes 2001; 50:S58-S61.
28. Ricordi C. Islet transplanation: a brave new world. Diabetes 2003; 52:1595-1603.
29. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-30.
30. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and inter- leukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55:40-9.
31. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF- kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813-20.
32. Zauli G, Corallini F, Bossi F, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110:536-43.
33. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009; 66: 841-51.
34. Ashkenazi A. Directing cancer cells to self-destruct with proapoptotic receptor agonists. Nat Rev Drug Discov 2008; 7: 1001-12.
35. Lancaster JM, Sayer R, Blanchette C, et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 2003; 9: 762-6.
36. Ehrhardt H, Fulda S, Schmid I, et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003; 22: 3842-52.
37. Secchiero P, Zerbinati C, Rimondi E, et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004; 61: 1965-74.
38. Morel J, Audo R, Hahne M, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005; 280: 15709-18.
39. Campioni D, Corallini A, Zauli G, Possati L, Altavilla G, Barbanti-Brodano G. HIV type 1 extracellular tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hu Retroviruses 1995; 11: 1039-48.
40. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S. Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 1996; 271: 22961-4.
41. Zauli G, Visani G, Bassini A, et al. Nuclear translocation of protein kinase C- and - isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid (ATRA). Br J Haematol 1996; 93: 542-50.
42. 133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 1998; 160: 3891-8.
43. Hunter I, Nixon GF. Spatial compartimentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells. Lipids rafts are essential for TNF- alpha-mediated activation of RhoA but dispensable for the activation of the NF-kappaB and MAPK pathways. J Biol Chem 2006; 281: 34705-34715.
44. Song JH, Tse MC, Bellail A, et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007; 67: 6946-6955.
45. Lincz LF, Yeh TX, Spencer A. TRAIL-induced eradication of primary tumor cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001; 15: 1650-1657.
46. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 2001; 15: 921-8.
47. Mirandola P, Ponti C, Gobbi G, et al. Activated human NK and CD8+T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL- mediated cytotoxicity. Blood 2004; 104: 2418-24.
48. Kim K, Fisher MJ, Xu SQ, et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335-46.
49. Campioni D, Secchiero P, Corallini F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005; 166: 557-63.
50. Secchiero P, Zerbinati C, di Iasio MG, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 8: 395-403.
51. Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168(3): 1356-61.
52. Sedger LM, Glaccum MB, Schuh JC, et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 2002; 32: 2246-54.
53. Ikeda T, Hirata S, Fukushima S, Matsunaga Y, Ito T, Uchino M, Nishimura Y, Senju S. Dueal effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. Jimmunol 2010; 185: 5259-67.
54. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, Chen YH. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 2003; 52: 2274-8.
55. Zauli G, Toffoli B, di Iasio MG, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin- induced diabetes. Diabetes 2010; 59: 1261-5.
56. Mi QS, Ly D, Lamhamedi-Cherradi SE, et al. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 2003; 52: 1967-75.
57. Appelman LJ, Tzachanis D, Grader-Beck T, van Puijenbroek AA, Boussiotis VA. Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics. J Mol Med 2001; 78: 673-83.
58. - mice. Diabetologia 2011; 54: 3157-67.
59. Bernardi S, Zauli G, Tikellis C, et al. TNF-related apoptosis- inducing ligand significantly attenuates metabolic abnormalities in high fat fed mice reducing adiposity and systemic inflammation. Clin Sci 2012 May 23. [Epub ahead of print].
60. Kang S Park SY, Lee HJ, Yoo YH. TRAIL upregulates decoy receptor 1 and mediates resistance to apoptosis in insulin-secreting INS-1 cells. Biochem Biophys Res Comm 2010; 396: 731-5.
61. Dirice E, Kahraman S, Elpek GO, Aydin C, Balci MK, Omer A, Sanlioglu S, Sanlioglu AD. TRAIL and DcR1 expressions are differentially regulated in the pancreatic islets of STZ- versus CY- applied NOD mice. Exp Diabetes Res 2011;2011: 625813.
62. Kang S, Park EJ, Joe Y, Seo E, Park MK. Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice. Endocrinology 2010; 151: 5638-46.
63. Maxwell PR, Timms PM, Chandran S, Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 2001; 18: 777-80.
64. Descamps FJ, Martens E, Ballaux F, Geboes K, Opdenakker G. In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes. J Pathol 2004; 204: 555-61.
65. Xue M, Thompson PJ, Clifton-Bligh R, Fulcher G, Gallery ED, Jackson C. Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type 1 diabetes. Int J Biochem Cell Biol 2005; 37: 2406-16.
66. Han X, Sun Y, Scott S, Bleich D. Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and b-cells. Diabetes 2001; 50: 1047-55.
67. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009; 8, 417-29.
68. Secchiero P, Candido R, Corallini F, et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiathero- sclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006; 114, 1522-30.
69. Michowitz Y, Goldstein E, Roth A, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005; 45: 1018-24.
70. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006; 184: 446-7.
71. Secchiero P, Corallini F, Ceconi C, et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PloS One 2009; 4: e4442.
72. Toffoli B, Bernardi S, Candido R, et al. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012; 30(3): 1257-60.
73. Lorz C, Benito-Martin A, Boucherot A, et al. The death ligand TRAIL in diabetic nephropathy. JASN 2008; 19: 904-14.
74. Secchiero P, Perri P, Melloni E, et al. Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjuntival sac fluid of patients with diabetes affected by proliferative retinopathy. Diabet Med 2011; 28: 1277-8.
75. Sanlioglu AD, Griffith TS, Omer A, et al. Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes. J Cell Biochem 2008; 104: 710-20.